PortfoliosLab logoPortfoliosLab logo
IDNA vs. XBI
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

IDNA vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IDNA achieves a 9.51% return, which is significantly higher than XBI's 4.78% return.


IDNA

1D
-2.18%
1M
-2.18%
YTD
9.51%
6M
10.53%
1Y
41.74%
3Y*
6.48%
5Y*
-8.26%
10Y*

XBI

1D
-4.39%
1M
-2.04%
YTD
4.78%
6M
8.21%
1Y
57.84%
3Y*
14.12%
5Y*
0.26%
10Y*
8.35%
*Multi-year figures are annualized to reflect compound growth (CAGR)

IDNA vs. XBI - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
9.51%17.26%-0.72%-7.63%-42.28%-3.98%54.30%20.83%
XBI
SPDR S&P Biotech ETF
4.78%35.89%1.01%7.60%-25.87%-20.45%48.33%14.57%

Correlation

The correlation between IDNA and XBI is 0.90, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.90

Correlation (3Y)
Calculated over the trailing 3-year period

0.90

Correlation (5Y)
Calculated over the trailing 5-year period

0.90

Correlation (All Time)
Calculated using the full available price history since Jun 14, 2019

0.91

The correlation between IDNA and XBI has been stable across timeframes, ranging from 0.90 to 0.91 - a consistent structural relationship.

IDNA vs. XBI - Sectors Allocation Comparison


Sectors
IDNA
XBI

Healthcare

97.8%
99.8%

Industrials

0.4%

-

Basic Materials

-

0.2%

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

0.2%

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

IDNA
97.8%
XBI
99.8%

Industrials

IDNA
0.4%
XBI

-

Basic Materials

IDNA

-

XBI
0.2%

Communication Services

IDNA

-

XBI

-

Consumer Cyclical

IDNA

-

XBI

-

Consumer Defensive

IDNA

-

XBI

-

Energy

IDNA

-

XBI

-

Financial Services

IDNA

-

XBI
0.2%

Real Estate

IDNA

-

XBI

-

Technology

IDNA

-

XBI

-

Utilities

IDNA

-

XBI

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IDNA vs. XBI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDNA
IDNA Risk / Return Rank: 5757
Overall Rank
IDNA Sharpe Ratio Rank: 4949
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 5050
Sortino Ratio Rank
IDNA Omega Ratio Rank: 4343
Omega Ratio Rank
IDNA Calmar Ratio Rank: 7979
Calmar Ratio Rank
IDNA Martin Ratio Rank: 6464
Martin Ratio Rank

XBI
XBI Risk / Return Rank: 7575
Overall Rank
XBI Sharpe Ratio Rank: 6868
Sharpe Ratio Rank
XBI Sortino Ratio Rank: 6868
Sortino Ratio Rank
XBI Omega Ratio Rank: 6161
Omega Ratio Rank
XBI Calmar Ratio Rank: 9292
Calmar Ratio Rank
XBI Martin Ratio Rank: 8888
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IDNA vs. XBI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


IDNAXBIDifference

Sharpe ratio

Return per unit of total volatility

1.71

2.28

-0.57

Sortino ratio

Return per unit of downside risk

2.48

3.14

-0.66

Omega ratio

Gain probability vs. loss probability

1.28

1.37

-0.09

Calmar ratio

Return relative to maximum drawdown

4.09

6.37

-2.28

Martin ratio

Return relative to average drawdown

11.79

19.55

-7.76

IDNA vs. XBI - Sharpe Ratio Comparison

The current IDNA Sharpe Ratio is 1.71, which is comparable to the XBI Sharpe Ratio of 2.28. The chart below compares the historical Sharpe Ratios of IDNA and XBI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


IDNAXBIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.71

2.28

-0.57

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.29

0.01

-0.30

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.26

Sharpe Ratio (All Time)

Calculated using the full available price history

0.10

0.36

-0.26

Drawdowns

IDNA vs. XBI - Drawdown Comparison

The maximum IDNA drawdown since its inception was -68.26%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for IDNA and XBI.


Loading charts...

Drawdown Indicators


IDNAXBIDifference

Max Drawdown

Largest peak-to-trough decline

-68.26%

-63.89%

-4.37%

Max Drawdown (1Y)

Largest decline over 1 year

-10.66%

-9.72%

-0.94%

Max Drawdown (3Y)

Largest decline over 3 years

-29.73%

-32.99%

+3.26%

Max Drawdown (5Y)

Largest decline over 5 years

-68.26%

-54.71%

-13.55%

Max Drawdown (10Y)

Largest decline over 10 years

-63.89%

Current Drawdown

Current decline from peak

-46.01%

-26.16%

-19.85%

Average Drawdown

Average peak-to-trough decline

-36.24%

-20.93%

-15.31%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.70%

3.17%

+0.53%

Volatility

IDNA vs. XBI - Volatility Comparison

The current volatility for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) is 7.24%, while SPDR S&P Biotech ETF (XBI) has a volatility of 9.43%. This indicates that IDNA experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IDNAXBIDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.24%

9.43%

-2.19%

Volatility (6M)

Calculated over the trailing 6-month period

18.21%

20.31%

-2.10%

Volatility (1Y)

Calculated over the trailing 1-year period

24.51%

25.57%

-1.06%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

28.42%

32.17%

-3.75%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

29.53%

32.00%

-2.47%

IDNA vs. XBI - Expense Ratio Comparison

IDNA has a 0.47% expense ratio, which is higher than XBI's 0.35% expense ratio.


Dividends

IDNA vs. XBI - Dividend Comparison

IDNA's dividend yield for the trailing twelve months is around 1.08%, more than XBI's 0.34% yield.


PositionTTM20252024202320222021202020192018201720162015
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.08%1.18%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%0.00%0.00%
XBI
SPDR S&P Biotech ETF
0.34%0.37%0.15%0.02%0.00%0.04%0.20%0.00%0.28%0.24%0.26%0.61%

Frequently Asked Questions


IDNA and XBI have a correlation of 0.90, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

XBI has higher volatility (9.43%) compared to IDNA (7.24%). In terms of maximum drawdown, IDNA dropped -68.26% vs XBI's -63.89%.

On 5-year performance, XBI leads with 0.26% vs -8.26% for IDNA. On fees, XBI is cheaper at 0.35% per year. On volatility, IDNA has been the lower-risk option at 7.24%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, XBI has performed better with a 0.26% return vs -8.26%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

XBI is cheaper with a 0.35% expense ratio, compared with 0.47% for IDNA.

IDNA has the higher dividend yield at 1.08%, compared with 0.34% for XBI.

IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index, while XBI tracks S&P Biotechnology Select Industry Index. They also come from different issuers: iShares and State Street. Their fees differ too: 0.47% for IDNA and 0.35% for XBI.

XBI currently has the higher Sharpe Ratio (2.28 vs 1.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for IDNA and XBI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer